Immunoprecise Stock Price, News & Analysis

ImmunoPrecise Antibodies (IPA) and Biotheus have entered into a Material Transfer and Evaluation Agreement (MTEA) for the development of a bispecific therapy against solid tumors. Biotheus will evaluate Talem Therapeutics' AI-enhanced TATX-20 lead candidate for potential use in creating novel bispecific antibodies to treat hypoxic solid tumors.

The collaboration aims to combine IPA's AI-driven antibody discovery expertise with Biotheus' bispecific engineering capabilities. If successful, Biotheus plans to further develop the bispecific molecules, targeting the creation of a clinically successful product for treating hypoxic solid tumors resistant to current therapies.

This strategic partnership could accelerate the development of innovative cancer treatments and potentially lead to breakthrough clinical outcomes, bringing value to both companies and patients in need of advanced treatment options.

ImmunoPrecise Antibodies (NASDAQ: IPA) announces significant progress in rabbit monoclonal antibody development using its proprietary B Cell Select® platform. The company's technology has been instrumental in advancing two novel antibodies, OR502 and OR641, for OncoResponse Inc. into clinical trials for cancer treatment.

OR502, targeting LILRB2, has entered Phase I/II trials for advanced solid tumors, showing an excellent safety profile. OR641, a dual antagonist targeting LILRB1 and LILRB2, is undergoing IND-enabling studies. Both antibodies have demonstrated superior ability to reverse immunosuppression in preclinical models.

IPA's B Cell Select® platform has been used in over 200 antibody programs, consistently delivering high-quality therapeutic candidates. The company is now offering more complex therapeutic rabbit antibody campaigns as a partnering model, reinforcing its position in the rapidly advancing field of rabbit monoclonal antibody therapeutics.

ImmunoPrecise Antibodies (IPA) reported financial results for Q1 FY25, ending July 31, 2024. The company achieved $5.3 million in revenue, with two of its three sites showing double-digit growth. IPA's AI-driven platform, LENSai, successfully developed antibodies end-to-end using computer simulations for a challenging Tumor Microenvironment target. BioStrand is expanding its presence on the AWS Marketplace, potentially opening new revenue streams. Talem Therapeutics and BioStrand are collaborating to enhance lead therapeutic assets using LENSai.

Financial highlights include:

• Project revenue: $4.9 million
• R&D expenses: $1.6 million
• Net loss: $4.0 million or $(0.15) per share
• Cash balance: $4.0 million as of July 31, 2024

ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutic research company, has announced its upcoming financial results and business highlights for Q1 FY2025. The company will host a conference call and webcast on September 16, 2024, at 10:30 AM ET to discuss these results. IPA will issue a press release with financial details prior to the call.

Participants can join the conference call via various dial-in numbers or through a webcast link available on the company's IR pages. The event will include a Q&A session following management's presentation. Investors are encouraged to review IPA's periodic reports for a comprehensive understanding of the company's operations and financial condition.

ImmunoPrecise Antibodies (NASDAQ: IPA) has announced its participation in the H.C. Wainwright's 26th Annual Global Investment Conference from September 9-11, 2024. The event will be held both in-person at the Lotte New York Palace Hotel in Manhattan and virtually. IPA's management team will be conducting one-on-one meetings with investors and interested parties.

The conference provides a platform for companies in sectors like biotech and life sciences to network, present, and meet with investors. Admission is free for qualified investors. Those interested in scheduling appointments with IPA can contact Jennifer K. Zimmons at Quantum Media. For registration and more information, visit the HCW Events website.

ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutics company, has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The notification, received on August 19, 2024, states that IPA's common shares closed below $1.00 for 30 consecutive business days from July 5 to August 15, 2024, violating Nasdaq Rule 5450(a)(1). This notification does not immediately affect IPA's listing or trading status on Nasdaq and is not a notice of imminent delisting. The company now has a specified period to regain compliance by meeting the minimum bid price requirement.

ImmunoPrecise Antibodies (IPA) has achieved a significant milestone in antibody engineering using its LENSai technology. The company successfully engineered highly specific antibodies to target a tumor microenvironment protein with previously unknown structure, entirely through computer simulations. This breakthrough demonstrates LENSai's potential to revolutionize drug discovery by:

1. Overcoming the challenge of designing therapeutics without prior structural knowledge
2. Producing antibodies that bind exclusively to the oncology target under specific conditions
3. Avoiding binding to similar proteins on healthy cells, potentially reducing side effects

This achievement could lead to faster, more efficient, and cost-effective development of targeted cancer therapies, addressing the industry's high failure rates and lengthy development timelines.

ImmunoPrecise Antibodies (IPA) reported record revenue of $24.5 million for fiscal year 2024, a 19% increase from the previous year. The company achieved significant milestones, including:

1. Expansion of laboratory facilities in Oss, Netherlands
2. Launch of commercial LENSai API for AI-powered solutions
3. Strategic collaborations with InterSystems and PGxAI
4. Introduction of advanced AI models for drug discovery

Despite the revenue growth, IPA reported a net loss of $27.2 million, including a $15 million impairment charge related to BioStrand's goodwill and intangible assets. The company's cash position stood at $3.5 million as of April 30, 2024, with reduced cash burn compared to the previous year.

ImmunoPrecise Antibodies (NASDAQ: IPA) has rescheduled its fiscal year 2024 financial results and business highlights release from July 25 to July 29, 2024. The company will host an earnings conference call via webcast at 10:30 am Eastern Time on the same day. The delay is to allow auditors additional time to complete valuation calculations on goodwill and intangible assets, ensuring accurate financial data and regulatory compliance.

Investors can access the live audio webcast through IPA's Investor Relations website. Participants can join the conference call using the provided toll-free and international dial-in numbers, using the Conference ID 9236374. A replay of the call will be available on the company's website following the conference.